Canadian Pharmacies Fight Back

The Medicare prescription drug benefit is a direct attack on Canadian pharmacies that ship drugs to US consumers--and those pharmacies are fighting back.

"Drug companies, not elderly Americans, are the real beneficiaries of the new Medicare prescription drug plan," the press release declares. For Big Pharma companies in the US, the headline is all too familiar: It could appear on a proclamation issued by Democratic critics of the new Part D benefit, a policy paper commissioned by Public Citizen, or an angry letter to the editor in almost any newspaper across the country.

But the press release didn’t come from one of the usual suspects. It didn’t even come from the US. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.